Home Cart Sign in  
Chemical Structure| 13137-64-9 Chemical Structure| 13137-64-9

Structure of Periplocin
CAS No.: 13137-64-9

Chemical Structure| 13137-64-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Periplocin is a cardiotonic steroid isolated from Periploca forrestii. Periplocin promotes tumor cell apoptosis and inhibits tumor growth. Periplocin has the potential to facilitate wound healing through the activation of Src/ERK and PI3K/Akt pathways mediated by Na/K-ATPase .

Synonyms: Periplocoside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Periplocin

CAS No. :13137-64-9
Formula : C36H56O13
M.W : 696.82
SMILES Code : O=C1OCC([C@H]2CC[C@]3(O)[C@]4([H])CC[C@]5(O)C[C@@H](O[C@H]6C[C@H](OC)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](C)O6)CC[C@]5(C)[C@@]4([H])CC[C@]23C)=C1
Synonyms :
Periplocoside
MDL No. :MFCD01745141
InChI Key :KWBPKUMWVXUSCA-AXQDKOMKSA-N
Pubchem ID :14463159

Safety of Periplocin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Periplocin

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
NCM460 44.95 ± 3.59 μM 24 h NCM460 cells showed higher tolerance to periplocin PMC10621285
RKO 0.12 μM to 0.82 μM 24 h Periplocin significantly inhibited CRC cell growth and induced apoptosis PMC10621285
LOVO 0.12 μM to 0.82 μM 24 h Periplocin significantly inhibited CRC cell growth and induced apoptosis PMC10621285
HT29 0.12 μM to 0.82 μM 24 h Periplocin significantly inhibited CRC cell growth and induced apoptosis PMC10621285
SW620 0.12 μM to 0.82 μM 24 h Periplocin significantly inhibited CRC cell growth and induced apoptosis PMC10621285
HCT116 0.12 μM to 0.82 μM 24 h Periplocin significantly inhibited CRC cell growth and induced apoptosis PMC10621285
SW480 0.12 μM to 0.82 μM 24 h Periplocin significantly inhibited CRC cell growth and induced apoptosis PMC10621285
DLD-1 0.12 μM to 0.82 μM 24 h Periplocin significantly inhibited CRC cell growth and induced apoptosis PMC10621285
KYSE-150 50, 100, 200 ng/ml 24 h and 48 h CPP alone or in combination with TRAIL could inhibit the proliferation of ESCC cells and induce apoptosis. PMC6925860
YES-2 50, 100, 200 ng/ml 24 h and 48 h CPP alone or in combination with TRAIL could inhibit the proliferation of ESCC cells and induce apoptosis. PMC6925860
Eca-109 50, 100, 200 ng/ml 24 h and 48 h CPP alone or in combination with TRAIL could inhibit the proliferation of ESCC cells and induce apoptosis. PMC6925860
Peripheral blood lymphocytes (PBLs) 50, 100, 200, 400 ng/mL 72 h Periplocin had no effect on the proliferation of PBLs PMC8009539
Jurkat cells 50, 100, 200, 400 ng/mL 24, 48, 72 h Periplocin significantly inhibited the proliferation of Jurkat cells in a dose- and time-dependent manner PMC8009539
HuT 78 cells 50, 100, 200, 400 ng/mL 24, 48, 72 h Periplocin significantly inhibited the proliferation of HuT 78 cells in a dose- and time-dependent manner PMC8009539
MDCK-MDR1 cells 75 µM and 100 µM 120 min Evaluate the permeability of Periplocin in MDCK-MDR1 cells, showing that P-gp is involved in the transport of Periplocin. PMC4026310
MDCK cells 75 µM and 100 µM 120 min Evaluate the permeability of Periplocin in MDCK cells, showing that Periplocin has weak permeability. PMC4026310

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice SW480 xenograft model Intraperitoneal injection 15 mg/kg Once daily for two weeks Periplocin significantly inhibited the growth of CRC xenografts with minimal toxicity PMC10621285
BALB/c nude mice ESCC xenografted tumor Intraperitoneal injection 0.09 mg and 0.36 mg Every two days for 14 days CPP alone or in combination with TRAIL showed significant anti-tumor activity in vivo. PMC6925860

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.44mL

0.29mL

0.14mL

7.18mL

1.44mL

0.72mL

14.35mL

2.87mL

1.44mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories